These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26524700)

  • 21. Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.
    Gombar VK; Hall SD
    J Chem Inf Model; 2013 Apr; 53(4):948-57. PubMed ID: 23451981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of 14C-spermidine to melanin in vivo and in vitro.
    Tjälve H; Nilsson M; Larsson B
    Acta Physiol Scand; 1981 Jun; 112(2):209-14. PubMed ID: 7315415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin F2 alpha binding to bovine ocular and synthetic melanins in vitro.
    Aula P; Kaila T; Huupponen R; Salminen L; Iisalo E
    Pharmacol Toxicol; 1989 Aug; 65(2):100-3. PubMed ID: 2813281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the melanin affinity of haloperidol.
    Lydén A; Larsson B; Lindquist NG
    Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):230-43. PubMed ID: 7181580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between chemicals and melanin.
    Larsson BS
    Pigment Cell Res; 1993 Jun; 6(3):127-33. PubMed ID: 8234197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calculation of drug-melanin binding energy using molecular modeling.
    Raghavan PR; Zane PA; Tripp SL
    Experientia; 1990 Jan; 46(1):77-80. PubMed ID: 2298284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critically Assessing the Predictive Power of QSAR Models for Human Liver Microsomal Stability.
    Liu R; Schyman P; Wallqvist A
    J Chem Inf Model; 2015 Aug; 55(8):1566-75. PubMed ID: 26170251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of eye pigmentation on transscleral drug delivery.
    Cheruvu NP; Amrite AC; Kompella UB
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development.
    del Amo EM; Vellonen KS; Kidron H; Urtti A
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):215-26. PubMed ID: 25603198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of cellular retention of melanin bound drugs: Experiments and computational modeling.
    Bahrpeyma S; Reinisalo M; Hellinen L; Auriola S; Del Amo EM; Urtti A
    J Control Release; 2022 Aug; 348():760-770. PubMed ID: 35738465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QSAR: an in silico approach for predicting the partitioning of pesticides into breast milk.
    Agatonovic-Kustrin S; Morton DW; Celebic D
    Comb Chem High Throughput Screen; 2013 Mar; 16(3):223-32. PubMed ID: 23228029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives.
    Báthory G; Szüts T; Magyar K
    Pol J Pharmacol Pharm; 1987; 39(2):195-201. PubMed ID: 3124086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of drug binding to melanin using a melanin-based high-performance liquid chromatographic stationary phase and chemometric analysis of the chromatographic data.
    Kaliszan R; Kaliszan A; Wainer IW
    J Chromatogr; 1993 Jun; 615(2):281-8. PubMed ID: 8335705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of drug-melanin interactions to ocular pharmacology and toxicology.
    Salazar-Bookaman MM; Wainer I; Patil PN
    J Ocul Pharmacol; 1994; 10(1):217-39. PubMed ID: 8207328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
    Hattotuwagama CK; Doytchinova IA; Flower DR
    Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling drug-melanin interaction with theoretical linear solvation energy relationships.
    Lowrey AH; Famini GR; Loumbev V; Wilson LY; Tosk JM
    Pigment Cell Res; 1997 Oct; 10(5):251-6. PubMed ID: 9359620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretation of Ocular Melanin Drug Binding Assays. Alternatives to the Model of Multiple Classes of Independent Sites.
    Manzanares JA; Rimpelä AK; Urtti A
    Mol Pharm; 2016 Apr; 13(4):1251-7. PubMed ID: 26820602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QSAR-based permeability model for drug-like compounds.
    Gozalbes R; Jacewicz M; Annand R; Tsaioun K; Pineda-Lucena A
    Bioorg Med Chem; 2011 Apr; 19(8):2615-24. PubMed ID: 21458999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.